The Johnson & Johnson vaccine against the Coronavirus was declared safe and effective by the European authorities, despite the risks that were discovered after its use, and it would be used at the European level to immunize the population.
The European authorities say that the risks of vaccination with Johnson & Johnson serum are much lower than the benefits of obtaining immunity against the Coronavirus, so they recommend its use to protect the population against infection.
"The Johnson&Johnson vaccine is safe and effective!
EMA conclusions 20.04.2021 regarding the vaccine developed by the Johnson&Johnson company, with a single-dose regimen
The risk-benefit ratio for the vaccine against COVID-19 developed by the Johnson&Johnson company, named "COVID-19 Vaccine Janssen", remains unchanged - the benefits of vaccination against COVID-19 outweigh the risks of adverse effects.
The occurrence of conditions associating thrombosis and thrombocytopenia has been encountered extremely rarely in patients vaccinated with this serum – 8 cases have been reported in the US after 7 million administrations.
These conditions were found more frequently in people under the age of 60, mostly women, in the first 3 weeks after vaccination.
Until this moment, no risk factors have been identified that predispose to the occurrence of these events.
The product information (Summary of Product Characteristics and Package Leaflet) will be updated to include warning data regarding the risk of thrombocytopenia and coagulation disorders.
‼️ It is recommended to contact the doctor urgently if the following symptoms are observed in the first 3 weeks after vaccination:
- breathing difficulties;
- pain in the chest;
– swelling of the legs;
- strong and persistent abdominal pain;
– persistent headaches;
- blurry vision;
– small spots of blood under the skin at a distance from the site of vaccine administration.”
